

IN THE CLAIMS:

Claims 1-11 (**cancelled**).

Claim 12 (**new**): A combination comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof in amounts synergistically effective in the prevention or treatment of atherosclerosis.

Claim 13 (**new**): A pharmaceutical composition which comprises a combination as claimed in Claim 12 in association with a pharmaceutically acceptable diluent or carrier.

Claim 14 (**new**): A combination comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof in amounts synergistically effective in the prevention of cardiovascular events.

Claim 15 (**new**): A pharmaceutical composition which comprises a combination as claimed in Claim 14 in association with a pharmaceutically acceptable diluent or carrier.

Claim 16 (**new**): A combination as claimed in Claim 12 or claim 14 wherein candesartan is in the form of candesartan cilexetil.

Claim 17 (**new**): A kit comprising:

- a) candesartan or a pharmaceutically acceptable salt thereof in a first unit dosage form;
- b) rosuvastatin or a pharmaceutically acceptable salt thereof in a second unit dosage form; and
- c) container means for containing said first and second dosage forms; and optionally
- d) instructions for use in the prevention or treatment of atherosclerosis,

wherein the candesartan and rosuvastatin are present in said first and second unit dosage forms, respectively, in amounts synergistically effective in the treatment of atherosclerosis.

Claim 18 (**new**): A kit comprising:

- a) candesartan or a pharmaceutically acceptable salt thereof;
- b) rosuvastatin or a pharmaceutically acceptable salt thereof;
- c) container means for containing said first and second dosage forms; and
- d) instructions for the administration of said candesartan and said rosuvastatin in amounts synergistically effective in the prevention or treatment of atherosclerosis.

Claim 19 (**new**): A method of preventing or treating atherosclerosis in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a combination comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof.

Claim 20 (**new**): A method of preventing cardiovascular events in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a combination comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof.

Claim 21 (**new**): A method of preventing or treating an inflammatory disease or condition in a warm-blooded animal in need thereof, which comprises administering to said animal a combination comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof.

Claim 22 (**new**): The method of claim 21 wherein said inflammatory disease or condition is selected from ischemia-reperfusion injury to the heart, brain, kidneys, lungs or liver, radiation-induced injury, burn injury and peripheral vascular disease.

Claim 23 (**new**): A method of inhibiting expression of CD40 and/or metalloproteinases (MMPs) in a warm-blooded animal in need thereof, which comprises administering to said animal a combination comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof.

Claim 24 (**new**): A method of treating atherosclerosis in a warm-blooded animal in need thereof by inhibition of expression of CD40 and/or metalloproteinases (MMPs), which comprises administering to said animal a combination comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof.

Claim 25 (**new**): A method of inhibiting expression of LOX-1 in a warm-blooded animal in need thereof, which comprises administering to said animal a combination comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof.

Claim 26 (**new**): A method of treating atherosclerosis in a warm-blooded animal in need thereof by inhibition of expression of LOX-1, which comprises administering to said animal a combination comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof.